ImmunoHorizons · 2023
Augmenting Granzyme B-Expressing NK Cells by Invariant NKT Ligand-Loaded APCs in Patients with Postoperative Early Stage Non-Small Cell Lung Cancer: Results of a Randomized Phase II Study.
Клиническое исследование II фазыРандомизированное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iyoda Tomonori, Shimizu Kanako, Kawamura Masami, Shinga Jun, Watanabe Takashi, Fukunaga Koya, Mushiroda Taisei, Saka Hideo, Kitagawa Chiyoe, Shimamatsu Shin-Ichiro, Takenoyama Mitsuhiro, Suehiro Youko, Imai Takumi, Shintani Ayumi, Ito Suminobu, Fujii Shin-Ichiro
Аннотация
The balance between energy intake and energy expenditure determines whether we gain weight, and appetite regulatory circuits in the brain have a critical role in this energy balance. G protein-coupled receptors (GPCRs), the largest family of transmembrane proteins, have an important role in appetite regulation. They function in the leptin-melanocortin pathway of the hypothalamic arcuate nucleus, which plays a central role in the regulation of energy balance and appetite, integrating peripheral metabolic cues with central neural circuits to promote satiety. GPCRs also mediate the function of the orexigenic hormone ghrelin, the suppression of appetite and hedonic reward circuitry by serotonin, and the incretin receptors are targets for several drugs that currently dominate the weight loss market. Human genetic studies and animal models of obesity have revealed important physiological roles in appetite regulation and weight gain for several additional GPCRs, some of which are still classified as orphan receptors. In this review, we discuss twelve GPCRs with roles in appetite regulation, focussing on developments within the last 5-10 years where possible. We discuss evidence from animal models, proposed mechanisms of action, and relevance to human disease for each of these receptors. Finally, we evaluated, where applicable, the current position and future prospects for therapeutically targeting these receptors for use in treatments for weight loss or gain.